Sumatriptan and Lenalidomide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Sumatriptan (sumatriptan succinate) and Lenalidomide (lenalidomide). Common drug interactions include neuropathy peripheral among females and haemoglobin increased among males.

The phase IV clinical study analyzes what interactions people have when they take Sumatriptan and Lenalidomide. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Sumatriptan?

Sumatriptan has active ingredients of sumatriptan succinate. It is often used in migraine. eHealthMe is studying from 18,159 Sumatriptan users. Check the latest studies of Sumatriptan.

What is Lenalidomide?

Lenalidomide has active ingredients of lenalidomide. eHealthMe is studying from 52,881 Lenalidomide users. Check the latest studies of Lenalidomide.



On Jul, 10, 2026

18 people who take Sumatriptan and Lenalidomide together, and have interactions are studied.

Sumatriptan and Lenalidomide drug interactions.

What are the common drug interactions of Sumatriptan and Lenalidomide, by gender? *:

female:

  1. Neuropathy peripheral (surface nerve damage)
  2. Pruritus (severe itching of the skin)
  3. Embolism (obstruction of an artery, typically by a clot of blood or an air bubble)
  4. Pyrexia (fever)
  5. Neutropenia (an abnormally low number of neutrophils)
  6. Skin infection
  7. Surgery
  8. Acute febrile neutrophilic dermatosis (skin disease characterized by the sudden onset of fever, leukocytosis, and tender)
  9. Balance disorder
  10. Confusional state

male:

  1. Haemoglobin increased
  2. Brain injury
  3. Chronic lymphocytic leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell))
  4. Colitis ischaemic (due to infection of intestine impaired blood supply to colon)
  5. Encephalopathy (functioning of the brain is affected by some agent or condition)
  6. Pneumonia
  7. Pruritus (severe itching of the skin)
  8. Sinusitis (inflammation of sinus)
  9. Thrombocytopenia (decrease of platelets in blood)
  10. Viral upper respiratory tract infection

What are the common drug interactions of Sumatriptan and Lenalidomide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Sinusitis (inflammation of sinus)

40-49:

n/a

50-59:

  1. Embolism (obstruction of an artery, typically by a clot of blood or an air bubble)
  2. Pyrexia (fever)
  3. Skin infection
  4. Acute febrile neutrophilic dermatosis (skin disease characterized by the sudden onset of fever, leukocytosis, and tender)
  5. Chronic lymphocytic leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell))
  6. Colitis ischaemic (due to infection of intestine impaired blood supply to colon)
  7. Muscular weakness (muscle weakness)
  8. Pneumonia
  9. Thrombocytopenia (decrease of platelets in blood)

60+:

  1. Pruritus (severe itching of the skin)
  2. Neuropathy peripheral (surface nerve damage)
  3. Gaze palsy (disorders affecting the ability to move both eyes in the same direction)
  4. Posterior reversible encephalopathy syndrome (posterior reversible encephalopathy syndrome (pres), also known as reversible posterior leukoencephalopathy syndrome (rpls), is a syndrome characterized by headache, confusion, seizures and visual loss)
  5. Transplant
  6. Viral upper respiratory tract infection
  7. Neutropenia (an abnormally low number of neutrophils)
  8. Haemoglobin increased
  9. Surgery
  10. Balance disorder

What are the existing conditions these people have? *

  1. Multiple Myeloma (cancer of the plasma cells): 11 people, 61.11%
  2. Headache (pain in head): 3 people, 16.67%
  3. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 11.11%
  4. Diarrhea: 2 people, 11.11%
  5. Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 11.11%
  6. B-Cell Lymphoma Refractory (blood cancer affecting b cells-relapsed): 2 people, 11.11%
  7. Peripheral Motor Neuropathy (muscles in the body become progressively weaker over months to years): 2 people, 11.11%
  8. Polyneuropathy (neurological disorder that occurs when many peripheral nerves throughout the body malfunction simultaneously): 2 people, 11.11%
  9. Pain In Extremity: 2 people, 11.11%
  10. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Sumatriptan and Lenalidomide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Sumatriptan and Lenalidomide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Sumatriptan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Lenalidomide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Sumatriptan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lenalidomide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on sumatriptan succinate and lenalidomide (the active ingredients of Sumatriptan and Lenalidomide, respectively), and Sumatriptan and Lenalidomide (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: